Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 514971

Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years


Pavićević, Radomir; Bialk, Peter; Bubanović, Gordana; Krajna, Ana; Samaržija, Miroslav; Pavićević, Lukrecija
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years // Gene Functional Analysis
San Francisco (CA), Sjedinjene Američke Države, 2001. (poster, nije recenziran, sažetak, znanstveni)


CROSBI ID: 514971 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years

Autori
Pavićević, Radomir ; Bialk, Peter ; Bubanović, Gordana ; Krajna, Ana ; Samaržija, Miroslav ; Pavićević, Lukrecija

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Gene Functional Analysis / - , 2001

Skup
Cambridge Healthtech Institute's fifth annual «Gene Funcional analysis: Genome 2001» tri-conference

Mjesto i datum
San Francisco (CA), Sjedinjene Američke Države, 08.03.2001. - 09.03.2001

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
CYFRA 21-1; NSCLC; tumor marker

Sažetak
The clinical application of cytokeratin marker CYFRA 21-1 was standardized on 2000 patients. In all patients the star value of CYFRA 21-1 was determined before therapy (Roche Diagnoastics). Tumor marker CYFRA 21-1 was ssessed longitudinally 1 to 24 months after the therapy, or before the next therapy. On eto three months after the surgical treatment in 87% of the patients the marker values decreased to the healthy population level...

Izvorni jezik
Engleski

Znanstvena područja
Biologija, Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Klinika za plućne bolesti "Jordanovac"


Citiraj ovu publikaciju:

Pavićević, Radomir; Bialk, Peter; Bubanović, Gordana; Krajna, Ana; Samaržija, Miroslav; Pavićević, Lukrecija
Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years // Gene Functional Analysis
San Francisco (CA), Sjedinjene Američke Države, 2001. (poster, nije recenziran, sažetak, znanstveni)
Pavićević, R., Bialk, P., Bubanović, G., Krajna, A., Samaržija, M. & Pavićević, L. (2001) Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years. U: Gene Functional Analysis.
@article{article, author = {Pavi\'{c}evi\'{c}, Radomir and Bialk, Peter and Bubanovi\'{c}, Gordana and Krajna, Ana and Samar\v{z}ija, Miroslav and Pavi\'{c}evi\'{c}, Lukrecija}, year = {2001}, keywords = {CYFRA 21-1, NSCLC, tumor marker}, title = {Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years}, keyword = {CYFRA 21-1, NSCLC, tumor marker}, publisherplace = {San Francisco (CA), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }
@article{article, author = {Pavi\'{c}evi\'{c}, Radomir and Bialk, Peter and Bubanovi\'{c}, Gordana and Krajna, Ana and Samar\v{z}ija, Miroslav and Pavi\'{c}evi\'{c}, Lukrecija}, year = {2001}, keywords = {CYFRA 21-1, NSCLC, tumor marker}, title = {Clinical applicability of tumor marker CYFRA 21-1 in patients with NSCLC: a longitudinal study of 500 patients during 2 years}, keyword = {CYFRA 21-1, NSCLC, tumor marker}, publisherplace = {San Francisco (CA), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }




Contrast
Increase Font
Decrease Font
Dyslexic Font